JP MORGAN/CALL/EDWARDS LIFESCIENCES/135/0.1/20.06.25 | Real-time Bid/Ask 03:00:05 2024-06-03 am EDT | ||
| 0.11 EUR / 0.26 EUR | +23.33% |
|
| 1 month | -6.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.15 | -.--% |
| 24-05-30 | 0.15 | 0.00% |
| 24-05-29 | 0.15 | -6.25% |
| 24-05-28 | 0.16 | -5.88% |
| 24-05-27 | 0.17 | -5.56% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 06:46 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK8CJ5 |
| ISIN | DE000JK8CJ53 |
| Date issued | 2024-04-26 |
| Strike | 135 $ |
| Maturity | 2025-06-20 (383 Days) |
| Parity | 10 : 1 |
| Emission price | 0.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.23 € |
|---|---|
| Lowest since issue | 0.14 € |
| Spread | 0.15 € |
| Spread % | 57.69% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
- Stock Market
- Warrants
- Warrant
